One notable example is the Aurora A inhibitor MLN8237, which overcomes resistance to BCR-ABL kinase inhibitors, in chronic myeloid leukemia (CML) [22]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.